Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

DB1038: Ph I started

February 24, 2017 2:19 AM UTC

Dauntless began a crossover, U.S. Phase I trial to compare intranasal DP1038 vs. subcutaneous Sandostatin octreotide acetate in about 32 healthy volunteers. Dauntless is developing DP1038 under sectio...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Dauntless Pharmaceuticals Inc.

BCIQ Target Profiles

Growth hormone receptor